- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03914443
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
November 8, 2023 updated by: National Cancer Center, Japan
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma FRONTiER Trial
The main purpose of this study is to evaluate the safety of the neoadjuvant therapy, nivolumab with CF (5-FU, CDDP) or nivolumab with DCF (5-FU, CDDP, DTX), for locally advanced esophageal carcinoma.
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tokyo, Japan
- National Cancer Center Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion criteria:
- Endoscopic biopsy of esophageal primary lesion histologically diagnosed as squamous cell carcinoma, adenosquamous carcinoma, or basal cell carcinoma
- All esophageal cancer lesions are localized in the thoracic esophagus
- Patients are classified as clinical stage T1N1-3M0 or T2-3N0-3M0 in the UICC-TNM classification 8th edition
- The age is over 20 years old and under 75 on the enrollment date
- PS 0-1
- With or without measurable lesions
- Patients who have no medical history of treatment for esophageal cancer
- Patients who have no medical history of chemotherapy, radiotherapy, and endocrine therapy, including treatment for other types of cancer
- The results of laboratory tests within 14 days before enrollment meet the inclusion criteria
- Esophageal cancer radical surgery (R0) by open-chest surgery (or thoracoscopic surgery) and laparotomy (or laparoscopic surgery) is judged possible
- Patients who have no complication or history of thyroid dysfunction
- Patients who have no complication or history of autoimmune disease
- Patients who don't have treatment with systemic corticosteroids (dose of 10mg/day over in prednisolone equivalent) or immunosuppressants within 14 days before enrollment
- Patients who have no complication or history of pneumonitis or pulmonary fibrosis which had been diagnosed by imaging tests or physical examination
- For females, who have agreed with contraception from start of investigational drug administration to 5 months after last dose of an investigational drug. For males who have agreed with contraception from start of investigational drug administration to 7 months after last dose of an investigational drug.
- Obtained written informed consent from patients"
Exclusion criteria:
- Patients who have active multiple cancers
- Patients who have an infectious disease that is active and need the systemic treatment
- Positive with HBs antigen, HCV-RNA or anti-HIV antibody, or anti-HTLV-1 antibody tests
- Negative with HBs antigen test and positive with anti HBs antibody or anti HBc antibody tests, and positive with HBV-DNA quantitative test
- Pregnant, suspected pregnant, or lactating
- Patients who have Psycosis or psychiatric symptoms are judged inappropriate for participation in the trial
- Patients who need the treatment with continued use of flucytosine, phenytoin, or warfarin potassium
- Patients who have a medical history of allergy to iodine
- Patients who have hypersensitivity to docetaxel, cisplatin, and drug-containing polysorbate 80
- Patients who have a complication or a history of highly sensitive reactions to antibody formulations
- Even if insulin or oral hypoglycemic agent is continued use, the result of HbA1c test is 6.5% or more in JDS or 6.9% or more in NGSP
- Patients who have advanced pulmonary emphysema, which is observed by pulmonary function test or CT test
- Patients who have uncontrollable hypertension
- Patients who have unstable angina or a medical history of myocardial infarction within 6 months before enrollment
- Patients who have diverticulitis or symptomatic peptic ulcer disease
- Patients who have a history of transplantation therapy, such as hematopoietic stem cell transplantation
- Patients who have a medical history of treatment with an anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, anti-CD137 antibody, anti-CTLA-4 antibody, or any other antibody for inhibition or modulation of T cell costimulatory pathway or cancer vaccine."
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A
"Nivolumab: 360 mg, every 3 week 5-FU: 800 mg/m^2, every 3 week CDDP: 80 mg/m^2, every 3 week "
|
240 mg or 360 mg
Other Names:
750 or 800 mg^2
Other Names:
70 or 80 mg/m^2
Other Names:
|
Experimental: Cohort B
"Nivolumab: 240 mg lead-in followed by 360 mg, every 3 week 5-FU: 800 mg/m^2, every 3 week CDDP: 80 mg/m^2, every 3 week "
|
240 mg or 360 mg
Other Names:
750 or 800 mg^2
Other Names:
70 or 80 mg/m^2
Other Names:
|
Experimental: Cohort C
"Nivolumab: 360 mg, every 3 week 5-FU: 750 mg/m^2, every 3 week CDDP: 70 mg/m^2, every 3 week DTX: 70mg/m^2, every 3 weeks"
|
240 mg or 360 mg
Other Names:
750 or 800 mg^2
Other Names:
70 or 80 mg/m^2
Other Names:
70 mg/m^2
Other Names:
|
Experimental: Cohort D
"Nivolumab: 240 mg lead-in followed by 360 mg, every 3 week 5-FU: 750 mg/m^2, every 3 week CDDP: 70 mg/m^2, every 3 week DTX: 70mg/m^2, every 3 weeks"
|
240 mg or 360 mg
Other Names:
750 or 800 mg^2
Other Names:
70 or 80 mg/m^2
Other Names:
70 mg/m^2
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of participants with dose limiting toxicities (DLTs)
Time Frame: from initial dose to 30 post-operative days
|
To evaluate the safety of combination chemotherapy with nivolumab as neoadjuvant Tx
|
from initial dose to 30 post-operative days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rate (RR): percentage of participants with with a best response of CR or PR
Time Frame: from baseline to date of disease progression, approximately 24 months
|
To evaluate the efficacy of combination chemotherapy with nivolumab as neoadjuvant Tx
|
from baseline to date of disease progression, approximately 24 months
|
Pathological complete response rate
Time Frame: from baseline to operation, average of 10 weeks after initial dose
|
To evaluate the efficacy of combination chemotherapy with nivolumab as neoadjuvant Tx
|
from baseline to operation, average of 10 weeks after initial dose
|
Radical resection rate
Time Frame: at operation, average of 10 weeks after initial dose
|
To evaluate the efficacy of combination chemotherapy with nivolumab as neoadjuvant Tx
|
at operation, average of 10 weeks after initial dose
|
Treatment completion rate
Time Frame: from baseline to operation, average of 10 weeks after initial dose
|
To evaluate the efficacy of combination chemotherapy with nivolumab as neoadjuvant Tx
|
from baseline to operation, average of 10 weeks after initial dose
|
Adverse event (AE) expression rate
Time Frame: up to 30 postoperative days
|
To evaluate the safety of combination chemotherapy with nivolumab as neoadjuvant Tx
|
up to 30 postoperative days
|
Progression-free survival (PFS)
Time Frame: from baseline to date of disease progression or death, approximately 24 month
|
To evaluate the efficacy of combination chemotherapy with nivolumab as neoadjuvant Tx
|
from baseline to date of disease progression or death, approximately 24 month
|
Overall survival (OS)
Time Frame: from baseline to date of death, approximately 24 month
|
To evaluate the efficacy of combination chemotherapy with nivolumab as neoadjuvant Tx
|
from baseline to date of death, approximately 24 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Ken Kato, MD/PhD, Department of Gastrointestinal Medical Oncology, National cancer center hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 7, 2019
Primary Completion (Actual)
February 1, 2023
Study Completion (Estimated)
March 1, 2024
Study Registration Dates
First Submitted
April 11, 2019
First Submitted That Met QC Criteria
April 12, 2019
First Posted (Actual)
April 16, 2019
Study Record Updates
Last Update Posted (Estimated)
November 9, 2023
Last Update Submitted That Met QC Criteria
November 8, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Neoplasms, Squamous Cell
- Carcinoma
- Carcinoma, Squamous Cell
- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Docetaxel
- Cisplatin
- Fluorouracil
- Nivolumab
Other Study ID Numbers
- JCOG1804E
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced Esophageal Squamous Cell Carcinoma
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingLocally Advanced Unresectable Esophageal Squamous CarcinomaChina
-
Emory UniversityAstex Pharmaceuticals, Inc.RecruitingHead and Neck Carcinoma of Unknown Primary | Locally Advanced Head and Neck Squamous Cell Carcinoma | Locally Advanced Hypopharyngeal Squamous Cell Carcinoma | Locally Advanced Laryngeal Squamous Cell Carcinoma | Locally Advanced Nasopharyngeal Squamous Cell Carcinoma | Locally Advanced Oropharyngeal...United States
-
Memorial Sloan Kettering Cancer CenterRecruitingSkin Cancer | Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Locally Advanced Skin Squamous Cell Carcinoma | Locally Advanced Cutaneous Squamous Cell Carcinoma | Locally Advanced Squamous Cell Carcinoma | Locally Advanced Squamous Cell Carcinoma of the SkinUnited States
-
Cancer Institute and Hospital, Chinese Academy...Akeso Pharmaceuticals, Inc.Not yet recruitingMetastatic Esophageal Squamous Cell Carcinoma | Unresectable Esophageal Squamous Cell Carcinoma | Locally Advanced Esophageal Squamous Cell Carcinoma
-
Jiangsu Cancer Institute & HospitalRecruitingLocally Advanced Esophageal CarcinomaChina
-
National Taiwan University HospitalRecruitingLocally Advanced Esophageal Squamous Cell CarcinomaTaiwan
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Zhongshan People's Hospital... and other collaboratorsRecruitingEsophageal Squamous Cell Carcinoma | Locally Advanced Esophageal Squamous Cell CarcinomaChina
-
The First Affiliated Hospital of Zhengzhou UniversityJiangsu HengRui Medicine Co., Ltd.RecruitingLocally Advanced Esophageal Squamous Cell CarcinomaChina
-
Sun Yat-sen UniversityXiangya Hospital of Central South University; Wuhan University; Zhujiang Hospital and other collaboratorsRecruitingLocally Advanced Esophageal Squamous Cell CarcinomaChina
-
The First Affiliated Hospital of Zhengzhou UniversityNot yet recruitingResectable Locally Advanced Esophageal Squamous Cell Carcinoma
Clinical Trials on Nivolumab
-
Universitair Ziekenhuis BrusselNot yet recruiting
-
Brown UniversityBristol-Myers Squibb; The Miriam Hospital; Rhode Island Hospital; Women and Infants...Terminated
-
Bristol-Myers SquibbRecruitingMelanomaSpain, United States, Italy, Chile, Greece, Argentina
-
Baptist Health South FloridaBristol-Myers Squibb; NovoCure Ltd.TerminatedRecurrent GlioblastomaUnited States
-
HUYABIO International, LLC.Bristol-Myers SquibbRecruitingUnresectable or Metastatic Melanoma | Progressive Brain MetastasisSpain, United States, Italy, Japan, Belgium, France, New Zealand, Brazil, Korea, Republic of, Australia, Germany, Singapore, Czechia, Austria, South Africa, United Kingdom, Puerto Rico
-
Jason J. Luke, MDArray BioPharmaActive, not recruitingMelanoma | Renal Cell Carcinoma | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell CarcinomaUnited States
-
Michael B. Atkins, MDBristol-Myers Squibb; Hoosier Cancer Research NetworkActive, not recruitingAdvanced Renal Cell CarcinomaUnited States
-
Bristol-Myers SquibbCompletedLung CancerItaly, United States, France, Russian Federation, Spain, Argentina, Belgium, Brazil, Canada, Chile, Czechia, Germany, Greece, Hungary, Mexico, Netherlands, Poland, Romania, Switzerland, Turkey, United Kingdom
-
IRCCS San RaffaeleBristol-Myers SquibbRecruiting
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingHepatocellular Carcinoma (HCC)Taiwan